Benzinga’s Top Pre-Market NASDAQ Losers (JAZZ, SAFM, PDLI, COCO)
Posted in: Earnings, News, Short Ideas, Downgrades, FDA, Pre-Market Outlook, Intraday Update, Markets, Analyst Ratings, Trading Ideas
Jazz Pharmaceuticals Inc (NASDAQ: JAZZ) dipped 25.22% to $7.65 in the pre-market session. US FDA panel has rejected JAZZ’s drug for treating the pain disorder fibromyalgia.
Sanderson Farms Inc (NASDAQ: SAFM) lost 4.56% to $41.19 in the pre-market session. SAFM has reported weaker-than-expected Q3 results.
PDL BioPharma Inc (NASDAQ: PDLI) fell 2.76% to $5.29 in the pre-market session. PDLI’s quarterly earnings dipped 35.10% y/y.
Corinthian Colleges Inc (NASDAQ: COCO) slipped 2.00% to $4.40 in pre-market trading. Analysts at ThinkEquity Partners downgraded COCO from “buy” to “hold.”
Read more from Benzinga's Company news.
(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We're Loving
